A Call for Clarity: Hemp Industry Specialist Testifies on FDA’s Regulatory Failures

The hemp industry stands at a pivotal moment, caught between its vast potential and the regulatory haze that stifles its growth. On April 9, 2025, a significant Hemp Industry Event unfolded as a congressional committee invited a hemp industry specialist to testify on the U.S. Food and Drug Administration’s (FDA) struggles to regulate hemp-derived products effectively. This hearing wasn’t just another bureaucratic exercise—it was a clarion call from businesses and advocates begging for federal guidance to legitimize and stabilize an industry projected to reach $16 billion by 2030. The testimony laid bare the FDA’s shortcomings, spotlighting the chaos of unregulated markets and the urgent need for reform.

The Hemp Boom and Its Regulatory Bottleneck

Hemp’s meteoric rise began with the 2018 Farm Bill, which legalized its cultivation by removing it from the Controlled Substances Act. Defined as cannabis with less than 0.3% THC, hemp opened doors to products like CBD oils, textiles, and even biodegradable plastics. By 2024, the U.S. hemp market was valued at $8.5 billion, with CBD alone accounting for nearly 60% of sales. Yet, this growth has been a double-edged sword. The FDA’s sluggish response to regulating hemp-derived products—especially CBD—has left businesses navigating a patchwork of state laws and inconsistent standards. The congressional hearing underscored this disconnect, with the hemp specialist emphasizing that the absence of clear federal rules fuels a “wild west” market.

The specialist, representing the U.S. Hemp Roundtable, painted a vivid picture: companies are desperate for a framework to ensure product safety and consumer trust. Without it, illicit products—often mislabeled or contaminated—flood the market. A 2023 study found that 47% of tested CBD products contained inaccurate THC levels, with some exceeding legal limits. This not only endangers consumers but also undermines legitimate businesses struggling to compete. The hearing revealed a stark truth: the FDA’s inaction has created a regulatory vacuum, and the industry is pleading for Congress to fill it.

Voices from the Field: Businesses Beg for Standards

The Hemp Industry News buzzing around the hearing highlighted a unified cry from stakeholders. Small farmers, manufacturers, and retailers shared stories of uncertainty. One Kentucky farmer, who pivoted from tobacco to hemp, described investing $200,000 in cultivation only to face inconsistent state testing protocols that rendered his crop unsellable. Manufacturers echoed this frustration, noting that without FDA guidelines, they risk costly lawsuits over labeling disputes. The specialist testified that businesses aren’t asking for deregulation—they’re begging for sensible regulation to level the playing field.

Data backs their plea. The Brightfield Group reported in 2024 that 70% of hemp businesses cited regulatory uncertainty as their top challenge, surpassing even market competition. The hearing exposed how the FDA’s hesitation stems partly from its cautious approach to CBD’s health claims. While the agency acknowledges CBD’s therapeutic potential—evidenced by the 2018 approval of Epidiolex for epilepsy—it insists on rigorous clinical trials before endorsing broader use. Yet, this slow pace clashes with the market’s reality, where 1 in 7 Americans already uses CBD regularly, according to a 2023 Gallup poll. The specialist argued that delaying regulation doesn’t protect consumers—it exposes them to untested products.

The Cost of Inaction: A Flood of Illicit Products

A striking point from the Hemp Industry Update during the hearing was the proliferation of counterfeit and unsafe hemp products. The specialist cited cases of vape cartridges laced with synthetic cannabinoids, sold under the guise of “natural” CBD. In 2024 alone, the FDA issued 22 warning letters to companies for misbranded hemp products, a drop in the bucket compared to the thousands operating unchecked. These illicit goods don’t just harm consumers—they erode trust in the industry. A 2022 Consumer Reports survey found that 64% of Americans worry about CBD product safety, a statistic the specialist used to underscore the urgency of federal oversight.

The economic toll is equally alarming. Legitimate hemp businesses lose an estimated $2 billion annually to black-market competitors, according to the Hemp Business Journal. The hearing highlighted how this chaos stems from the FDA’s failure to enforce existing laws, like the Food, Drug, and Cosmetic Act, which could regulate CBD as a dietary supplement. Instead, the agency’s indecision leaves states to set their own rules, creating a fractured market. For instance, while Colorado caps THC in hemp products at 0.3%, Florida allows up to 0.5%, confusing consumers and complicating interstate commerce. The specialist urged Congress to push the FDA for a unified standard, warning that delays only deepen the crisis.

A Path Forward: Balancing Innovation and Safety

The hearing wasn’t just about airing grievances—it was about solutions. The specialist proposed a roadmap for the FDA to regulate hemp products as dietary supplements, a move supported by 80% of industry leaders, per a 2024 Hemp Industry Daily poll. This would require setting clear manufacturing standards, mandating third-party testing, and establishing dosage guidelines. Such measures could reduce adverse events, like the 1,000+ CBD-related health complaints reported to the FDA since 2019. The specialist also called for increased funding to bolster the FDA’s enforcement capacity, noting its current budget for hemp oversight is a mere $5 million annually—less than 0.1% of its total budget.

Beyond regulation, the hearing touched on hemp’s broader potential. The specialist highlighted its environmental benefits: hemp sequesters 15 tons of CO2 per hectare, outpacing most crops. It also requires 50% less water than cotton, making it a sustainable alternative for textiles. These facts resonated with lawmakers, who see hemp as a rural economic driver. In 2023, hemp farming supported 45,000 jobs, primarily in states like Oregon and North Carolina. By addressing regulatory gaps, Congress could unlock further growth, ensuring these benefits reach more communities.

The Road Ahead: A Defining Moment

As the hearing concluded, the Hemp Industry Event left a lasting impression: the FDA’s regulatory shortcomings are no longer a niche issue but a national concern. The specialist’s testimony wasn’t just a critique—it was a rallying cry for action. Lawmakers appeared receptive, with some pledging to draft legislation urging the FDA to expedite hemp regulations. The SAFE Banking Act, which could ease financial barriers for hemp businesses, was also mentioned as a potential companion measure. Yet, skepticism lingers. The FDA’s history of foot-dragging—six years after the Farm Bill, it’s still “evaluating” CBD guidelines—suggests change won’t come easily.

For now, the hemp industry waits, poised between frustration and hope. The hearing exposed the stakes: a thriving sector that could redefine agriculture and wellness, or a missed opportunity lost to regulatory inertia. As the specialist put it, “We’re not asking for a free pass—we’re asking for a fair shot.” With $16 billion in potential growth on the line, Congress and the FDA face a choice: lead with clarity or let chaos prevail. The hemp industry, and the millions it serves, deserve nothing less than a decisive answer.

Discover the future of hemp with D Squared WorldWide! As the hemp industry surges toward a $16 billion market by 2030, our premium, lab-tested CBD oils, textiles, and wellness products meet the highest standards, ensuring safety and trust. Amid FDA regulatory challenges, D Squared WorldWide leads with transparency and quality, capitalizing on hemp’s eco-friendly potential—sequestering 15 tons of CO2 per hectare. Don’t miss out on this booming opportunity! Partner with us to offer top-tier hemp products that customers love. Schedule a call today to explore wholesale options and elevate your business with D Squared WorldWide’s innovative solutions!

Reference:

1. Corroon, J., Mackay, D., & Dolphin, W. (2020). Labeling of cannabidiol products: a public health perspective. Cannabis and Cannabinoid Research, 5(4), 274-278. https://doi.org/10.1089/can.2019.0101

2. Engeli, B., Lachenmeier, D., Diel, P., Guth, S., Fernandez, M., Roth, A., … & Mally, A. (2025). Cannabidiol in foods and food supplements: evaluation of health risks and health claims. Nutrients, 17(3), 489. https://doi.org/10.3390/nu17030489

Johnson, E., Kilgore, M., & Babalonis, S. (2022). Label accuracy of unregulated cannabidiol (cbd) products: measured concentration vs. label claim. Journal of Cannabis Research, 4(1). https://doi.org/10.1186/s42238-022-00140-1